

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 22 November 2024 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company's 2024 Notice of Annual General Meeting were passed by the requisite majorities at today's AGM.

All resolutions were passed and decided by way of poll.

About Immutep

Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:

Catherine Strong, Sodali & Co
+61 (0)406 759 268; catherine.strong@sodali.com

U.S. Media:

Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immune.com

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

Immutep Limited
Annual General Meeting
Friday, 22 November 2024
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of the Remuneration Report	Ordinary	596,200,866 92.03%	47,633,655 7.35%	3,993,376 0.62%	703,521	602,999,485 92.63%	48,008,574 7.37%	703,521	Carried	NO
2. Re-election of Dr Frederic Triebel as a Director	Ordinary	611,144,777 92.00%	48,692,848 7.33%	4,466,526 0.67%	314,637	618,690,238 92.70%	48,692,848 7.30%	415,864	Carried	NA
3. Ratification of Prior Issue of Shares	Ordinary	330,366,704 94.64%	14,663,443 4.20%	4,060,951 1.16%	310,057,253	337,466,590 95.80%	14,804,670 4.20%	310,057,253	Carried	NA
4. Approval of Grant of Performance Rights to Mr Marc Voigt	Ordinary	527,517,214 79.44%	132,616,315 19.97%	3,869,630 0.58%	614,719	534,232,087 80.07%	132,951,234 19.93%	614,719	Carried	NA
5. Approval of Grant of Performance Rights to Dr Federic Triebel	Ordinary	519,537,519 79.28%	132,007,456 20.14%	3,804,557 0.58%	9,261,496	526,421,011 79.94%	132,108,683 20.06%	9,261,496	Carried	NA
6. Approval of Potential Termination Benefits for Eligible Executive of the Company	Ordinary	564,531,110 87.24%	78,756,646 12.17%	3,793,153 0.59%	5,610,610	571,403,198 87.87%	78,857,873 12.13%	5,610,610	Carried	NA
7. Approval of the Issue of Performance Rights and/or Options under the Company's Executive Incentive Plan	Ordinary	582,786,467 90.32%	58,619,301 9.08%	3,833,785 0.59%	2,536,715	589,425,495 90.90%	58,994,220 9.10%	2,536,715	Carried	NA
8. Approval of Proportional Takeover Provisions (Special Resolution)	Special	655,554,648 98.74%	4,477,543 0.67%	3,857,658 0.58%	737,629	662,592,468 99.33%	4,477,543 0.67%	737,629	Carried	NA

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.